Metformin and Esomeprazole in Treatment of Early Onset Preeclampsia
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Preeclampsia is globally responsible for tens of thousands of maternal and neonatal deaths
each year. Currently, there are no medical therapies to halt disease progression and
expectant management and delivery remain the mainstay of treatment. An important step in the
pathogenesis of preeclampsia is a poor placental invasion and the subsequent release of the
anti-angiogenic factors soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin
(sEng)into the maternal circulation. Given metformin and esomeprazole successfully mitigate
key pathogenic features of preeclampsia, the investigator will study whether combining
low-doses of metformin and esomeprazole may be additive or synergistic (or neither) in
reducing sFlt-1 and sEng secretion, and mitigating endothelial dysfunction, compared to
placebo.